High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma

Yan Cheng,Fumou Sun,Daisy V Alapat,Visanu Wanchai,David Mery,Wancheng Guo,Huojun Cao,Yuqi Zhu,Cody Ashby,Michael Anton Bauer,Intawat Nookaew,Eric R Siegel,Jun Ying,Jin-Ran Chen,Dongzheng Gai,Bailu Peng,Hongwei Xu,Clyde Bailey,Samer Al Hadidi,Carolina Schinke,Sharmilan Thanendrarajan,Maurizio Zangari,Marta Chesi,P Leif Bergsagel,Frits van Rhee,Siegfried Janz,Guido Tricot,John D Shaughnessy Jr,Fenghuang Zhan

DOI: https://doi.org/10.1016/j.xcrm.2023.101214

2023-10-17

Abstract:Multiple myeloma (MM) growth is supported by an immune-tolerant bone marrow microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) in tumor microenvironmental cells is associated with MM growth suppression. The absence of NEK2 leads to both fewer tumor-associated macrophages (TAMs) and inhibitory T cells. NEK2 expression in myeloid progenitor cells promotes the generation of functional TAMs when stimulated with MM conditional medium. Clinically, high NEK2 expression in MM cells is associated with increased CD8+ T effector memory cells, while low NEK2 is associated with an IFN-γ gene signature and activated T cell response. Inhibition of NEK2 upregulates PD-L1 expression in MM cells and myeloid cells. In a mouse model, the combination of NEK2 inhibitor INH154 with PD-L1 blockade effectively eliminates MM cells and prolongs survival. Our results provide strong evidence that NEK2 inhibition may overcome tumor immune escape and support its further clinical development.